Related papers: OPTIMUS: Predicting Multivariate Outcomes in Alzhe…

Brain positron emission tomography (PET) imaging is broadly used in research and clinical routines to study, diagnose, and stage Alzheimer's disease (AD). However, its potential cannot be fully exploited yet due to the lack of portable…

The joint analysis of biomedical data in Alzheimer's Disease (AD) is important for better clinical diagnosis and to understand the relationship between biomarkers. However, jointly accounting for heterogeneous measures poses important…

Alzheimer's disease is estimated to affect around 50 million people worldwide and is rising rapidly, with a global economic burden of nearly a trillion dollars. This calls for scalable, cost-effective, and robust methods for detection of…

Alzheimer s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, where early detection is essential for timely intervention and improved patient outcomes. Traditional diagnostic methods are…

Accurate and early diagnosis of Alzheimer's disease (AD) is critical for effective intervention and requires integrating complementary information from multimodal neuroimaging data. However, conventional fusion approaches often rely on…

Alzheimer's disease (AD) progresses through distinct stages, from early mild cognitive impairment (EMCI) to late mild cognitive impairment (LMCI) and eventually to AD. Accurate identification of these stages, especially distinguishing LMCI…

Alzheimer's disease is a progressive form of dementia that results in problems with memory, thinking, and behavior. It often starts with abnormal aggregation and deposition of beta amyloid and tau, followed by neuronal damage such as…

Cognitive decline is highly heterogeneous across individuals, which complicates prognosis, trial design, and treatment planning. We present the Personalized Cognitive Decline Assessment Digital Twin (PCD-DT), a multimodal and…

Nowadays, a lot of scientific efforts are concentrated on the diagnosis of Alzheimer's Disease (AD) applying deep learning methods to neuroimaging data. Even for 2017, there were published more than a hundred papers dedicated to AD…

This paper describes a multi-modal approach for the automatic detection of Alzheimer's disease proposed in the context of the INESC-ID Human Language Technology Laboratory participation in the ADReSS 2020 challenge. Our classification…

Alzheimer's disease and related dementias (AD/ADRD) represent a growing healthcare crisis affecting over 6 million Americans. While genetic factors play a crucial role, emerging research reveals that social determinants of health (SDOH)…

Timely and accurate diagnosis of neurodegenerative disorders, such as Alzheimer's disease, is central to disease management. Existing deep learning models require large-scale annotated datasets and often function as "black boxes".…

The application of machine learning algorithms to the diagnosis and analysis of Alzheimer's disease (AD) from multimodal neuroimaging data is a current research hotspot. It remains a formidable challenge to learn brain region information…

Age is one of the major known risk factors for Alzheimer's Disease (AD). Detecting AD early is crucial for effective treatment and preventing irreversible brain damage. Brain age, a measure derived from brain imaging reflecting structural…

Early and accurate diagnosis of Alzheimer Disease is critical for effective clinical intervention, particularly in distinguishing it from Mild Cognitive Impairment, a prodromal stage marked by subtle structural changes. In this study, we…

Alzheimer's disease is a progressive neurodegenerative disorder that remains challenging to predict due to its multifactorial etiology and the complexity of multimodal clinical data. Accurate forecasting of clinically relevant biomarkers,…

Predicting whether subjects with mild cognitive impairment (MCI) will convert to Alzheimer's disease is a significant clinical challenge. Longitudinal variations and complementary information inherent in longitudinal and multimodal data are…

Multi-modal biological, imaging, and neuropsychological markers have demonstrated promising performance for distinguishing Alzheimer's disease (AD) patients from cognitively normal elders. However, it remains difficult to early predict when…

Deep learning (DL) for predicting Alzheimer's disease (AD) has provided timely intervention in disease progression yet still demands attentive interpretability to explain how their DL models make definitive decisions. Recently,…

Alzheimer's disease (AD) is a growing global health challenge as populations age, and timely, accurate diagnosis is essential to reduce individual and societal burden. However, real-world AD assessment is hampered by incomplete,…